Payment overview · 2025
General Payments
$503.27
23 reported records · 14 companies
Healthcare provider profile · identity verified
William M Dixon, MD
Allopathic & Osteopathic Physicians|Family Medicine · PROSPERITY, SC · NPI 1710964416
Verified facts
What the public records show
CMS Open Payments records show William M Dixon, MD received $503.27 in general payments during 2025 across 23 reported records.
Lundbeck LLC accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.81 | 18.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.61 | 14.0% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $62.36 | 12.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.49 | 8.6% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $40.92 | 8.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.22 | 6.4% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $28.58 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.62 | 5.3% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.87 | 4.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.66 | 3.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.37 | 3.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.14 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.69 | 2.9% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $12.93 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $503.27 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $119.43 | 5 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $62.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.44 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $40.92 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $24.87 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $12.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 35 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 38 |
| Omeprazole | Omeprazole | 122 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 13 |
| Simvastatin | Simvastatin | 85 | 17 |
| Carvedilol | Carvedilol | 81 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 17 |
| Lisinopril | Lisinopril | 78 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 70 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 17 |
| Losartan Potassium | Losartan Potassium | 66 | 11 |
| Eliquis | Apixaban | 62 | suppressed |
| Gabapentin | Gabapentin | 61 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 12 |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Allopurinol | Allopurinol | 59 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | suppressed |
| Famotidine | Famotidine | 55 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 11 |
| Potassium Chloride | Potassium Chloride | 51 | 13 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Lorazepam | Lorazepam | 47 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | 12 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Furosemide | Furosemide | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 22 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $503.27 · 23 records | Lundbeck LLC | Barostim Neo System, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, Kerecis GraftGuide, Kerecis SurgiClose, Korlym, NEXPLANON, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, Senza, The Cologuard Plus Collection Kit, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error